81.8% Patients on GA Depot Demonstrated No Evidence of Disease Activity (NEDA) at 2 years GA Depot Has Potential to Address Multiple Sclerosis Treatment Burden and Improve Patient Compliance NESS ZIONA, Israel – Oct. 9th, 2018 – Mapi Pharma Ltd., a fully integrated,...
Once approved, this product could represent a significant milestone for patients with relapsing-remitting multiple sclerosis Mapi Pharma has completed an open-label Phase II clinical trial and is preparing to commence a pivotal Phase III clinical trial to support...
NESS ZIONA, Israel – February 6, 2018 – Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company, announced today that it will host a Key Opinion Leader (KOL) luncheon on its GA Depot, a novel long-acting depot formulation of glatiramer...
Ness Ziona, Israel, January 30, 2018 — Mapi Pharma Ltd announced today that the first patient has been treated with GA Depot in the company’s Phase II study for primary progressive multiple sclerosis (PPMS). Glatiramer acetate, the active material of...
Data Suggest that GA Depot Has Potential to Ease the Treatment Burden and Improve Patient Compliance in MS Patients on GA Depot Achieved a No Evidence of Disease Activity (NEDA) Score of 84.6% Phase III Trial Planned for 2018 NESS ZIONA, Israel – Oct. 31, 2017 – Mapi...
NESS ZIONA, Israel, August 17, 2017. Mapi Pharma Ltd., a privately held, fully integrated, clinical stage biopharmaceutical company has completed an investment round of $10 million by aMoon Fund. aMoon Fund is an Israeli investment firm focused on innovative Israeli... 